Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

EC Page; EK Bancroft; MN Brook; M Assel; M Hassan Al Battat; S Thomas; N Taylor; A Chamberlain; J Pope; HN Raghallaigh; DG Evans; J Rothwell; L Maehle; EM Grindedal; P James; L Mascarenhas; J McKinley; L Side; T Thomas; C van Asperen; H Vasen; LA Kiemeney; J Ringelberg; TD Jensen; PJS Osther; BT Helfand; E Genova; RA Oldenburg; C Cybulski; D Wokolorczyk; KR Ong; C Huber; J Lam; L Taylor; M Salinas; L Feliubadaló; JC Oosterwijk; W van Zelst-Stams; J Cook; DJ Rosario; S Domchek; J Powers; S Buys; K O'Toole; MGEM Ausems; RK Schmutzler; K Rhiem; L Izatt; V Tripathi; MR Teixeira; M Cardoso; WD Foulkes; A Aprikian; H van Randeraad; R Davidson; M Longmuir; MWG Ruijs; ATJM Helderman van den Enden; M Adank; R Williams; L Andrews; DG Murphy; D Halliday; L Walker; A Liljegren; S Carlsson; A Azzabi; I Jobson; C Morton; K Shackleton; K Snape; H Hanson; M Harris; M Tischkowitz; A Taylor; J Kirk; R Susman; R Chen-Shtoyerman; A Spigelman; N Pachter; M Ahmed; T Ramon y Cajal; J Zgajnar; C Brewer; N Gadea; AF Brady; T van Os; D Gallagher; O Johannsson; A Donaldson; J Barwell; N Nicolai; E Friedman; E Obeid; L Greenhalgh; V Murthy; L Copakova; S Saya; J McGrath; P Cooke

Journal article

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

EC Page, EK Bancroft, MN Brook, M Assel, M Hassan Al Battat, S Thomas, N Taylor, A Chamberlain, J Pope, HN Raghallaigh, DG Evans, J Rothwell, L Maehle, EM Grindedal, P James, L Mascarenhas, J McKinley, L Side, T Thomas, C van Asperen Show all

European Urology | Published : 2019

DOI: 10.1016/j.eururo.2019.08.019

Download PDF

Abstract

Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants: Men aged 40–69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. Outc..

View full abstract

University of Melbourne Researchers

Paul James Author

Declan Murphy Author

Sibel Saya Author

Geoffrey Lindeman Author

Related Projects (2)

The IMPACT Study

IDENTIFICATION OF MEN WITH A GENETIC PREDISPOSITION TO PROSTATE CANCER: TARGETED SCREENING IN MEN AT HIGHER GENETIC RISK AND CONTROLS – THE IMPACT STUDY

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This research is coordinated by the Institute of Cancer Research, London, UK, and is supported by grants from Cancer Research UK (grant references C5047/A21332, C5047/A13232, and C5047/A17528) and the Ronald and Rita McAulay Foundation. Judith Offman is supported by Cancer Research UK Programme Grant reference C8161/A16892. Mr. and Mrs. Jack Baker are acknowledged for supporting the study in NorthShore University HealthSystem, Evanston, IL, USA and Myriad Genetics Laboratory, Salt Lake City, UT, USA, for providing research BRCA testing rates for NorthShore University HealthSystem patients. We acknowledge funding from the National Institute for Health Research (NIHR) to the Biomedical Research Center at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, at Manchester University Foundation Trust (IS-BRC-1215-20007), the Oxford Biomedical Research Centre Program, and the Cambridge Clinical Research Centre, NIHR Cambridge Biomedical Research Centre. We acknowledge that in Australia, this project was cofunded by Cancer Council Tasmania and Cancer Australia (grant number 1006349 [2011-2013]), Prostate Cancer Foundation of Australia (grant number PCFA PRO4 [2008]), Cancer Councils of Victoria and South Australia (grant number 400048 [2006-2008]), the Victorian Cancer Agency Clinical Trial Capacity CTCB08_14, Cancer Australia and Prostate Cancer Foundation of Australia (2014-2016; grant number 1059423), and Translational grants EOI09_50. The Association of International Cancer Research funded data collection in The Netherlands (AICR 10-0596). We acknowledge funding from the Basser Center for BRCA (to Susan Domchek). This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748), a SPORE grant in Prostate Cancer to Dr. H. Scher (P50-CA92629), the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation. This workwas also supported in part by the NIHR Oxford Biomedical Research Centre Program in UK, the Swedish Cancer Society (CAN 2017/559), the Swedish Research Council (VR-MH project no. 2016-02974), and General Hospital in Malmo Foundation for Combating Cancer. We acknowledge funding from the Slovenian Research Agency, Research programme P3-0352. We thank CERCA Program/Generalitat de Catalunya for their institutional support. Elena Castro acknowledges funding from Prostate Cancer Foundation. We acknowledge the support of the Asociacion Espanola Contra el Cancer (AECC), the Instituto de Salud Carlos III (organismo adscrito al Ministerio de Economia y Competitividad), "Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa" (PI10/01422, PI13/00285, PIE13/00022, PI16/00563, JR18/00011 and CIBERONC), and the Institut Catala de la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338 and PERIS Project MedPerCan). We acknowledge funding support from Fundacao para a Ciencia e a Tecnologia to the IPO Porto study (project grant PTDC/DTP-PIC/1308/2014 to Manuel R. Teixeira and fellowship grant SFRH/BD/116557/2016 to Marta Cardoso).